An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

NCT02882126 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Subcutaneous Treprostinil

Sponsor

United Therapeutics

Collaborators

[object Object]